Ketoaminol, 100 pcs.

Pharmacotherapeutic group: renal failure treatment.

ATX code: V06DD

Pharmacological properties

Pharmacodynamics

Ketoaminol® is used in renal failure as a nutritional agent.

Ketoaminol® provides an intake of essential amino acids while minimizing nitrogen intake. After absorption, keto- and hydroxy acids can be transaminated to form their respective essential amino acids, with the amino group transferred from the substituted amino acids. Because of the reuse of the amino group, urea formation is slowed and the accumulation of uremic toxins is reduced. Keto- and hydroxyacids do not cause hyperfiltration in the remaining nephrons.

Keto supplements have a positive effect on renal hyperphosphatemia and secondary hyperparathyroidism. Moreover, it is possible to improve the course of osteodystrophy. Administration of Ketoaminol® together with a very low-protein diet reduces nitrogen intake while preventing adverse events due to malnutrition and insufficient protein intake with food.

Pharmacokinetics

The plasma kinetics of amino acids and their incorporation into metabolic pathways are well understood. It should be noted that absorption processes in uremic patients taking amino acids do not appear to disrupt their plasma concentrations, i.e., absorption is not impaired. Changes in plasma concentrations probably occur at stages following amino acid absorption; they are detected early in the disease.

The plasma concentrations of ketoacids in healthy volunteers increase within 10 minutes of oral administration. Individual ketoacid concentrations are increased up to five times of baseline. Maximum plasma concentrations are reached within 20-60 min, after 90 min, concentrations return to baseline. Thus, absorption from the gastrointestinal tract is very rapid. The simultaneous increase in plasma concentrations of keto acids and the corresponding amino acids indicates a high rate of transamination. Because of the physiological pathways of ketoacid utilization in the body, exogenous ketoacids appear to be rapidly incorporated into metabolic cycles. Keto acids undergo the same catabolic pathways as normal amino acids. No separate study of ketoacid excretion has been performed.

Indications

Active ingredient

Composition

How to take, the dosage

Interaction

Special Instructions

Serum calcium concentrations should be monitored regularly.

A sufficient caloric intake is necessary.

When used concomitantly with aluminum hydroxide serum phosphate concentrations should be monitored (see section “Interaction with other medicinal products”).

Ketoaminol® has no effect on the ability to drive and engage in other potentially hazardous activities requiring increased concentration and rapid psychomotor reaction.

Contraindications

Side effects

Pregnancy use